Received at least 45 Gy and no more than 66 Gy prior radiotherapy
Ambulatory with an ECOG performance status of 0 to 2 (Appendix C)
18 years of age or older
You may not be if
Received more than 25% of total bone marrow irradiated, total body or hemi-body irradiation or prior radioisotope therapy (except for benign thyroid disease)
Prior radiation therapy or chemotherapy within 4 weeks of start of study
Another active medical condition(s) or organ disease(s) that may compromise subject safety or interfere with safety and/or outcome evaluation of study drug
Laboratory abnormalities, including but not limited to: WBC \< 3000/uL, Absolute neutrophil count \< 1500/uL, Platelets \< 150,000/uL, Hemoglobin ≤ 9.0 gm/dL, Total bilirubin \> 1.5 x upper limit of normal for age, SGOT or SGPT \> 3 x upper limit of normal for age if no liver metastases or \> 5 x upper limit of normal for age in the presence of liver metastases, Serum creatinine \> 1.5 x upper limit of normal for age, 2+ proteinuria or casts indicative of intrinsic renal disease
Treatment with investigational drug, investigational biologic, or investigational therapeutic device within 28 days of initiating study treatment
Received prior stem cell transplantation
Clinically significant cardiac co-morbidities including congestive heart failure (New York Heart Association class III-IV heart disease), left ventricular ejection fraction \< 40%, unstable angina pectoris, serious cardiac arrhythmia requiring medication or pacemaker, myocardial infarction within past 6 months
Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters).
Uncontrolled hypertension as defined by systolic blood pressure \> 150 mm/Hg, diastolic blood pressure \> 100 mm/Hg or uncontrolled diabetes that would compromise subject safety or interfere with safety and/or outcome evaluation of study drug
Major surgery within 4 weeks of enrollment
Poor venous access and unable to receive study drug into a peripheral venous catheter
Significant traumatic injury within past 4 weeks
Ongoing or active infection requiring antibiotics or with fever \>38.1º C (\>101º F) within 3 days of first scheduled day of dosing
Receiving concurrent hemodialysis or peritoneal dialysis
Known positive for HIV, Hepatitis C (active, previously treated or both), or is Hepatitis B core antigen positive